ArticleCureus2025
Provider Perceptions of Over-the-Counter Progestin-Only Birth Control Pills in Urban, Suburban, and Rural Populations of Pennsylvania.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The Opill is an over-the-counter, progestin-only oral contraceptive and the first of its kind to free women from the need to obtain a prescription for birth control. Opill is approved in Pennsylvania, a remarkably diverse state containing urban, rural, and suburban regions spanning the state. As women gain easier access to birth control that does not require a medical provider's prescription, the Opill may help overcome healthcare gaps when seeking birth control methods. It is crucial to understand provider opinion on progestin-only pills (POPs), which influence patient education and use of the progestin-only pills to prevent unintended pregnancies. In this study, we aim to survey providers who prescribe birth control in Pennsylvania's rural, urban, and suburban regions to gain insight into their opinions of the Opill. Methodology The surveys were emailed to healthcare providers in OBGYN, family medicine, internal medicine, and pediatrics using Drexel University College of Medicine's affiliated clinical sites throughout Pennsylvania. The provider's demographics, knowledge, and attitudes toward Opill were collected. Results The survey was sent to 764 providers, and 60 (8%) completed it. Fifty-one (85%) participants did not receive any information from their institution regarding over-the-counter birth control pills, and 36 (61%) received no formal training on patient counseling for over-the-counter birth control. Unawareness of the availability of Opill among rural, suburban, and urban providers was 3 (75.0%), 11 (34.5%), and 6 (27.3%), respectively. Conclusions There is a notable lack of awareness and clinical training of the Opill within Pennsylvania's urban, suburban, and rural providers. Because of the lack of training, providers may be less likely to support and recommend Opill to patients as opposed to other oral contraceptives. As Opill continues to gain traction in the market, further studies are needed to determine whether provider training, perceptions, and recommendations regarding Opill will change over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.